PBYI Q3 2024 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M+43.5% YoY

Gross Profit

$51M63.9% margin

Operating Income

$22M27.4% margin

Net Income

$20M25.2% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+71.1%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$221M

Total Liabilities

$150M

Stockholders' Equity

$71M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$56M	+43.5%
Gross Profit	$51M	$43M	+20.1%
Operating Income	$22M	$9M	+157.2%
Net Income	$20M	$6M	+250.5%

Revenue Segments

Product

$56M70%

Royalty

$24M30%